All-trans retinoic acid restores gap junctional intercellular communication between oral cancer cells with upregulation of Cx32 and Cx43 expressions in vitro by Wang, Juan et al.
Med Oral Patol Oral Cir Bucal. 2013 Jul 1;18 (4):e569-77.                                                                                                                                             ATRA restores GJIC between oral cancer cells
e569
Journal section: Oral Medicine and Pathology
Publication Types: Research
All-trans retinoic acid restores gap junctional intercellular communication 
between oral cancer cells with upregulation of Cx32 and Cx43 expressions in vitro
Juan Wang 1, Yaohui Dai 1, Yulei Huang 1, Xiaohua Chen 2, Hong Wang 1, Yun Hong 1, Juan Xia 1, Bin Cheng 1
1 Ph.D, Department of Oral Medicine, The Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510060, China
2 M.M.S, Department of Oral Pathology, The Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou 510060, 
China
Correspondence:
Department of Oral Medicine
Guanghua School of Stomatology
Sun Yat-sen University 
Guangdong Provincial Key Laboratory of Stomatology
No.56, Lingyuanxi Road, Guangzhou
Guangdong 510055, People’s Republic of China
xiajuan@mail.sysu.edu.cn
Received: 31/07/2012
Accepted: 17/12/2012
Abstract
Objective: All-trans retinoic acid (ATRA) has been demonstrated to inhibit tumor growth by restoration of gap 
junctional intercellular communication (GJIC) via upregulation of connexin (Cx) expression in some solid tumors. 
However, the relationship between ATRA and GJIC remains unclear in oral squamous cell carcinoma (OSCC). 
The aim of this study was to investigate the effect of ATRA on the GJIC function of OSCC.
Study design: We measured the effects of ATRA on the viability and cell cycle distribution of SCC9 and Tca8113 
OSCC cells. The GJIC function was observed using the scrape-loading dye transfer technique, and the mRNA and 
protein levels of Cx32 and Cx43 were detected by qRT-PCR, Western blot, and immunofluorescence assays.
Results: ATRA inhibited the growth of OSCC cells in a dose- and time-dependent manner (P <0.05) and caused 
cell cycle arrest. ATRA-treated cells showed a 2.69-fold and 2.06-fold enhancement of GJIC in SCC9 and Tca8113 
cells, respectively (P <0.05). Moreover, ATRA induced upregulation of Cx32 and Cx43 at both the mRNA and 
protein levels in OSCC cells.
Conclusion: Our results indicated that restoration of GJIC via enhanced Cx32 and Cx43 expression might serve as 
a novel mechanism for the anti-tumor effect of ATRA in OSCC.
Key words: All-trans retinoic acid, oral squamous cell carcinoma, connexin, gap junctional intercellular com-
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Introduction
Gap junctions are intercellular channels that permit the 
direct exchange of ions and small molecules between 
adjacent cells. Gap junction channels are constructed 
of two hemichannels (connexons) provided by each ad-
jacent cell. These connexons are composed of integral 
plasma membrane proteins, termed connexins (Cxs). 
At present, approximately 21 connexin(Cx) isoforms 
have been characterized in the human genome (1). Gap 
junctional intercellular communication (GJIC) plays an 
important role in the maintenance of tissue homeostasis 
and control of cell growth and differentiation. The dis-
ruption of GJIC and abnormal expression of Cxs have 
been found in a series of human cancers and cell lines, 
including cervical carcinoma, colon cancer, and renal 
cell carcinoma (RCC) (2-4). Moreover, overexpression 
of Cx32 reduces the metastasis of RCC cells in vivo (4) 
and some anti-neoplastic agents were found to inhibit 
cell proliferation and enhance GJIC of SK-Hep-1 human 
hepatoma cells, which is associated with upregulation 
of Cx32 and Cx43 (5). These results raise the possibility 
that Cxs may be defined as tumor suppressors and that 
restoration of GJIC by induction of normal Cx expres-
sion may be a unique anti-tumor therapeutic strategy. 
Among the anti-tumor agents that can restore GJIC, the 
vitamin A metabolite all-trans retinoic acid (ATRA) has 
been found to increase the amount and phosphorylation 
of Cx43 and enhanced GJIC in hepatoma HepG2 cells 
(6). Chen et al. (7) has provided evidence that ATRA can 
significantly restore the impaired capacity of GJIC in 
prostate cancer and enhanced the efficiency of cell kill-
ing during suicide gene therapy against prostate cancer. 
Therefore, it is necessary to explore the role of ATRA in 
improving GJIC of human oral squamous cell carcinoma 
(OSCC), the sixth ranked malignant tumor worldwide. 
OSCC is the most common oral malignancy, and the 
5-year survival rate of OSCC has remained at approxi-
mately 50% in spite of recent advances in diagnosis and 
treatment (8). Therefore, prevention and treatment of 
OSCC are the focus of current research. Accumulating 
data demonstrate that ATRA and its derivatives play an 
important role in both the chemoprevention and treat-
ment of OSCC. ATRA has been previously shown to 
promote growth inhibition of OSCC cell lines and in-
hibit tumor growth in an OSCC xenograft solid-tumor 
model (9). However, the precise mechanism underlying 
the anti-tumor effect of ATRA is not yet fully under-
stood. Previous studies have shown that OSCC growth 
inhibition by ATRA is mainly related to cell cycle ar-
rest, cell apoptosis, and differentiation (10,11). Recently, 
Frank et al. (12) reported that human tongue squamous 
cell carcinoma cells were deficient in Cx43 expression. 
Our previous study showed that Cx43 expression de-
creased during 4-nitroquinoline-1-oxide–induced rat 
carcinogenesis (13). These results indicate that OSCC 
has aberrant GJIC. Moreover, studies have shown that 
the anti-tumor effects of ATRA on human hepatoma 
and prostate cancer cells are associated with resto-
ration of GJIC function and Cxs expression (6,7). As 
such, modulation of GJIC may be a novel mechanism 
underlying the anti-tumor effects of ATRA. Therefore, 
we proposed that effective intervention therapy with 
ATRA for OSCC may be correlated with GJIC and the 
specific mechanisms of this action are worthy of further 
study. In this study, we examined the effect of ATRA 
on gap junction function in OSCC cells and investigated 
the mRNA and protein expression of Cx subtypes.
Material and Methods
-Cell lines and cell culture
Two OSCC cell lines, SCC9 cell line (American Tissue 
Culture Collection, Manassas, VA, USA) and Tca8113 
(Shanghai Jiao Tong University College of Stomatolo-
gy, P.R. China) were routinely maintained in 1:1 mix of 
Dulbecco’s Modified Eagle Medium and Ham F12 me-
dium (DMEM/F12) and Roswell Park Memorial Insti-
tute (RPMI)-1640 medium, respectively, supplemented 
with 10% fetal bovine serum (FBS), 100 U/ml penicil-
lin, and 100 U/ml streptomycin. Primary human normal 
oral epithelial (NOE) cells were harvested from the gin-
gival mucosa of healthy patients who were undergoing 
impacted tooth extraction. Informed consent was ob-
tained. Isolated NOE cells were collected using an en-
zymatic method (14). Cells were fed with keratinocyte 
serum-free medium. Cells were used for experiments 
at passage 3. All cells were incubated in an humidified 
incubator at 37° with 5% CO2. All culture reagents were 
purchased from Gibco (Grand Island, NY, USA).
-Reagents 
ATRA was obtained from Sigma-Aldrich (St Louis, 
MO, USA) and dissolved in ethanol. The concentration 
of ethanol was kept under 0.1% throughout all the ex-
periments to avoid cytotoxicity.
-Cell viability analysis
Cell viability was determined by 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
assay. Briefly, cells (5000 cells/well in 96-well plates) 
were cultured with ATRA at different concentrations 
(0–100μM) for 24 h and 48 h. Then, 20 μl of MTT solu-
tion (5 mg ⁄ml in phosphate buffered solution; Sigma-
Aldrich) was added to each well. The cells were incu-
bated for 4 h at 37°, and the crystals were dissolved with 
150 μl of dimethylsulfoxide ( DMSO, Sigma-Aldrich). 
The optical density (OD) value of the solution was de-
termined at 490 nm in a microplate reader (Elx808; 
BioTek, Winooski, VT, USA). Cell viability was calcu-
lated according to the following formula: Cell viability 
(%) = OD450 (sample)/OD450 (control) ×100.
-Scrape-loading dye transfer assay
Scrape-loading and dye transfer (SL/DT) were used to 
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measure GJIC in SCC9, Tca8113, and NOE cells. The 
SL/DT method has been described in detail by el-Fouly 
et al. (15). In brief, OSCC cells plated on 6-well plates 
until 70–80% confluent were treated with ATRA for 
48h. Then, cells were washed twice with phosphate 
buffered solution (PBS) and scrape-loaded with a sur-
gical scalpel. After 5 min incubation with 0.05% Lu-
cifer Yellow dye (Invitrogen, Carlsbad, CA, USA) at 
room temperature, the dye solution was discarded and 
the cultures were rinsed with PBS and fixed in 4% (v/v) 
formaldehyde. Gap junctional dye transfer was ob-
served under a fluorescent microscope (Axiovert 200; 
Carl Zeiss, Hamburg, Germany). Cells that received 
Lucifer Yellow from the scrape-loaded cells were con-
sidered communicating. The quantification of intercel-
lular communication was accomplished by counting the 
numbers of cells communicating among the untreated 
and treated cells. GJIC was expressed as a percentage 
of the control (16).
-Quantitative real-time polymerase chain reaction 
(PCR)
Quantitative real-time PCR were performed to assay the 
mRNA expression of eight Cxs in OSCC cells exposed 
to ATRA or vehicle and NOE cells. Total RNA from 
cultured cells was isolated using TRIzol (Invitrogen) 
and reverse transcribed into cDNA with an ImProm-II 
reverse transcription system kit (BioRad, Hercules, CA, 
Genes                                       Primer sequences Length
Cx26 Forward  5’-GCTCCCTGTGGTGGACCTAC-3’
Reverse  5’-GCATGGAGAAGCCGTCGTAC-3’
102bp
Cx30 Forward  5’-ACTTTTTCCCGGTGTCCCAC-3’
Reverse  5’-TTTCGTGCCTGTAGTAGGCCA-3’
105 bp
Cx31 Forward  5’-TGCTGCACACTCTCTGGCAT-3’
Reverse  5’-AGGTCGGGCAATGTAGCAGT-3’
101 bp
Cx31.1 Forward  5’-GCAGCAAGGAAAGCTCAAGC-3’
Reverse  5’-CAGAAAGATGAGGTCACCCGA-3’
102 bp
Cx32 Forward  5’GACCCCCTACACCTGGAGGA3’
Reverse  5’-TCAAACAACAGCCGGAACAC-3’
101 bp
Cx37 Forward  5’-TTTCGAGTGTAACACGGCCC-3’
Reverse  5’-CGAAGAGGAACTGCAGCACC-3’
101 bp
Cx43 Forward  5’GGAAAGAGCGACCCTTACCAT-3’
Reverse  
5’CATATTTTTGAGACCCACAGTCTTTG-3’
73 bp
Cx45 Forward  5’GCT TCC TGA CTC GCC TGC TA-3’
Reverse  5’AGC TGT AAG GAC GAT CCG GA-3’
101 bp
β-actin Forward  5’-GCGCGGCTACAGCTTCA-3’
Reverse  5’-TCTCCTTAATGTCACGCACGAT-3’
59 bp
Table 1. Primer sequences used in real-time PCR.
Cx: connexin.
USA). The cDNA was analyzed by real-time PCR using 
a SYBR Green qPCR kit (Applied Biosystems, Foster 
City, CA, USA) and an Applied Biosystems (ABI) 7500 
Fast PCR instrument. All primers for each gene are list-
ed in table 1. PCR conditions were: 95° for 10 s followed 
by 40 cycles of 95° for 5 s and then 60° for 1 min. The 
2-ΔΔCt method was used to quantify the relative mRNA 
expression using β-actin as the endogenous control.
-Western blot analysis
Cells were lysed with 1% NP-40 lysis buffer (50 mM 
Tris, 150 mM NaCl, l mM EDTA, and 0.02% NaN3) 
supplemented with protease inhibitors (Roche, Indiana-
polis, IN, USA) for total protein extraction. The protein 
concentrations were measured using a BCA protein as-
say kit (Thermo Scientific, Rockford, IL, USA). Equal 
amounts of protein were loaded for SDS-PAGE and 
immunoblotted with the following primary antibodies: 
mouse monoclonal anti-Cx32 (Invitrogen; 1:800), mouse 
monoclonal anti-Cx43 (Invitrogen; 1:800), mouse mon-
oclonal anti-Cx45 (Millipore, Billerica, Massachusetts, 
USA; 1:500), and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, Invitrogen). After incubation with 
horseradish peroxidase-conjugated rabbit anti-mouse 
IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), the immunoreactive bands were detected us-
ing an enhanced chemiluminescence(ECL) detection 
system (Amersham Pharmacia, Piscataway, NJ, USA). 
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-Immunofluorescence analysis 
Immunofluorescent staining was used to verify the 
protein expression and examine the subcellular locali-
zation of Cx32 and Cx43. Cells were plated onto glass 
coverslips in six-well plates and treated with ATRA 
or vehicle for 48 h. Samples were fixed in 4% parafor-
maldehyde for 10 min, permeabilized with 0.1% Triton 
X-100 for 10 min, and blocked with 1% bovine serum 
albumin (BSA) in PBS for 30 min. Cells were incubated 
overnight at 4°C in 1:100 mouse anti-connexin 43 (Inv-
itrogen) or 1:50 mouse anti-Cx32 antibody (Invitrogen). 
The cells were then incubated for 1 h at room tempera-
ture with rabbit anti-mouse IgG Alexa 488 (Invitrogen; 
1:200). Subsequently, nuclei were counterstained with 
4’,6-diamidino-2-phenylindole(DAPI)for 10 min. Sam-
ples were photographed on a fluorescent microscope 
(Aiovert 200; Carl Zeiss).  
-Statistical analysis
Data were expressed as the mean ± standard deviation of 
at least three independent experiments. Statistical analy-
sis of the results was performed using a two-tailed Stu-
dent’s t-test or one-way ANOVA and post hoc multiple 
comparison test with SPSS software v.16.0 (SPSS, Chi-
cago, Illinois, USA). P <0.05 was considered significant.
Results
-ATRA inhibits cell viability 
As showed in table 2, ATRA (0–100 μM) induced cell 
growth inhibition of both SCC9 and Tca8113 cells in a 
dose-and time-dependent manner (P<0.05). After ATRA 
ATRA
(μmol/l)
SCC9 (OD value) Tca8113 ( OD value)
24h 48h 24h 48h
0 0.222±0.016 0.312±0.014 0.345±0.012 0.403±0.006
0.1 0.212±0.013 0.277±0.012* 0.331±0.004 0.354±0.013*
1.0 0.203±0.012* 0.264±0.008* 0.313±0.010* 0.342±0.011*
5.0 0.185±0.008* 0.261±0.025* 0.262±0.009* 0.261±0.002*
10 0.165±0.004* 0.232±0.011* 0.24±0.004* 0.216±0.008*
20 0.123±0.015* 0.147±0.009* 0.190±0.004* 0.175±0.005*
100 0.087±0.014* 0.068±0.011* 0.156±0.012* 0.085±0.005*
Table 2. Effect of ATRA on the viability of oral squamous cell carcinoma cells. 
ATRA: All-trans retinoic acid; OD: optical density.
*P<0.05 compared with control.
(20 μM) treatment for 48 h, the inhibition rate reached 
53.07% in SCC9 cells and 55.01% in Tca8113 cells; at 
the same time, the IC50 values were 19.43±1.67 μM and 
12.52±1.23 μM, respectively. The concentrations of 15 
μM ATRA for SCC9 and 10 μM for Tca8113 cells were 
determined as optional for subsequent experiments.
-ATRA enhances GJIC
In NOE cells, Lucifer Yellow was transmitted to more 
than six cell lines via gap junctions (Fig. 1). However, 
Lucifer Yellow was only visualized in cells adjacent to 
the scrape lines in SCC9 and Tca8113 cells. After ATRA 
treatment, SCC9 cells showed evident Lucifer Yellow-
coupling in 4–5 layers adjacent to the scrape line. 
ATRA induced a 2.69-fold increase in the number of 
cells that showed Lucifer Yellow in SCC9 cells as com-
pared with control-SCC9 cells(P=0.019) (Fig. 1). After 
exposure to ATRA, Tca8113 cells showed evident Luci-
fer Yellow-coupling in 3–4 layers adjacent to the scrape 
line. ATRA caused a 2.06-fold increase in the number 
of cells that were Lucifer Yellow-positive in Tca8113 as 
compared with control-Tca8113 cells (P=0.034).
-ATRA upregulates Cx mRNA expression  
Real-time PCR was performed to detect the expression of 
eight homologous connexin isoforms: Cx26, Cx30, Cx31, 
Cx31.1, Cx32, Cx37, Cx43, and Cx45 (Fig. 2). ATRA 
significantly increased the mRNA expression of Cx32, 
Cx43, and Cx45 in SCC9 cells (P <0.05). Compared with 
control-Tca8113 cells, ATRA enhanced the mRNA ex-
pression of five Cxs in Tca8113 cells, including Cx30, 
Cx31, Cx32, Cx43, and Cx45 (P <0.05). However, Cx32, 
Cx43, and Cx45 were the three most upregulated genes 
induced by ATRA in both cell lines. Compared with NOE 
cells, both SCC9 and Tca8113 cells showed low levels of 
Cx32, Cx43, and Cx45 mRNA without ATRA treatment. 
Whereas after exposure to ATRA, the expression of the 
Cx32, Cx43, and Cx45 mRNAs were increased by an av-
erage of 4.34-fold, 2.03-fold, and 2.13-fold, respectively, 
in SCC9 cells. ATRA treatment also produced a signifi-
cant increase in mRNA expression of Cx32, Cx43, and 
Cx45 in Tca8113 cells (2.1-fold, 1.68-fold, and 1.68-fold, 
respectively, as compared to the control).
Effects of ATRA on Cx protein levels and localization
Protein expression of Cx32, Cx43, and Cx45 in SCC9 
and Tca8113 cells was examined by Western blot analy-
sis. The protein levels of Cx32, Cx43, and Cx45 were 
decreased in both cell lines as compared with NOE cells 
(Fig. 3). After ATRA treatment, SCC9 cells showed a 
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Fig. 1. ATRA increased GJIC between oral squamous cell carcinoma cells. A) SCC9 and Tca8113 cells 
were treated with ATRA or vehicle for 48h, after which GJIC was assessed by the scrape-loading and 
dye transfer method as described in Materials and Methods. Human normal oral epithelial (NOE) cells 
showed at least six rows of fluorescent cells from scrape. The Lucifer Yellow fluorescent cells of SCC9 
and Tca8113 were only observed in areas near to scrape. After ATRA treatment, SCC9 cells showed a 
significantly increased Lucifer Yellow transfer through gap junction than controls. ATRA treatment also 
improved GJIC of Tca8113 cells. Bar: 50μМ. B) The quantification of cells that show positive dye staining. 
*P < 0.05 relative to ethanol control.
Fig. 2. Real-time PCR analysis of the Cx mRNA expression in OSCC cells after ATRA treatment.
The gene expression levels in SCC9 and Tca8113 cells were analyzed separately and were calculated in terms of 
fold change by using the 2-ΔΔCt equation. Colums represent the mean of three determinations for each treatment 
condition. Error bars represent the range factor difference (2-ΔΔCt-ΔCt SD and 2ΔΔCt+ΔCt SD). Statistical significance 
was calculated by Student t test; *P< 0.05 relative to control.
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Fig. 3. Western blot and immunofluorescence analysis of Cx32, Cx43 and Cx45 protein expression in 
OSCC cells after ATRA treatment. The expressions of Cx32 (A) and Cx43 (B) significantly decreased 
in SCC9 and Tca8113 cells as compared with human normal oral epithelial (NOE) cells. After ATRA 
treatment for 48h, the protein expressions of Cx32 (A) and Cx43 (B) increased in both SCC9 and Tca8113 
cells. (C) Compared with human normal oral epithelial (NOE) cells, the protein expression of Cx45 also 
decreased in SCC9 and Tca8113 cells. However, ATRA treatment did not changed the protein level of 
Cx45 in SCC9 and Tca8113 cells. (D)ATRA treatment significantly increased the abundance of Cx32 
and Cx43 protein and improved localization of fluorescent spots on the plasma membrane of treated 
SCC9 and Tca8113 cells, compared with those of controls, where the fluorescence appears scattered in 
the cytoplasm. #P<0.01 relative to normal oral epithelial cells; *P<0.05 relative to ethanol control. Bar: 
20μМ.
13-fold increase in Cx32 protein levels compared with 
control-SCC9, while Tca8113 cells showed a 3.6-fold in-
crease in the Cx32 protein (Fig. 3). ATRA also induced 
a 2.6-fold and 1.6-fold increase of Cx43 protein expres-
sion in SCC9 and Tca8113 cells, respectively (Fig. 3). 
However, both SCC9 and Tca8113 cells displayed no 
significant change in Cx45 protein concentration after 
ATRA treatment (Fig. 3). 
The subcellular localization of Cxs was examined by 
immunofluorescence assay. In treated SCC9 cells, 
green fluorescence was located throughout the cell 
membrane and cytoplasm and the Cx32 and Cx43 
staining increased and localized at the cell membrane. 
In contrast, untreated cells displayed a small number 
of positive spots and diffuse cytoplasmic staining for 
Cx32 and Cx43. In Tca8113 cells, ATRA treatment 
produced similar findings to those observed in SCC9 
cells and increased the membrane-association and 
levels of Cx32 and Cx43 as compared with control-
Tca8113 cells (Fig. 3).
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Discussion
ATRA, an active and natural derivative of vitamin A, 
plays an important role in many physiological func-
tions, such as growth, differentiation, reproduction, 
apoptosis, homeostasis, and fetal development (17). In 
clinical studies, retinoids have been shown to have a 
promising role in the chemoprevention and chemother-
apy of human head and neck cancers. ATRA has been 
used to control oral lesions of lichen planus as well as to 
prevent and reverse the progression of oral leukoplakia 
to malignant tumors. It has also shown an anti-tumor 
therapeutic effect on OSCC (18, 19). The mechanisms of 
ATRA action are not completely understood, although 
several mechanisms have been reported, including mod-
ulation of differentiation and proliferation, induction of 
apoptosis and cell cycle arrest, and downregulation of 
telomerase activity (20,21). Recently, several studies 
have demonstrated that ATRA has the ability to modu-
late GJIC in some cancers, and alteration of GJIC may 
be a new mechanism for the chemopreventative/chemo-
therapeutic actions of ATRA. However, there is little 
evidence for the effect of ATRA on the GJIC in human 
OSCC cells. In the present study, we demonstrated that 
ATRA significantly inhibited the cell viability in two 
OSCC cell lines, SCC9 and Tca8113. Moreover, ATRA 
enhanced the functional gap junctions of OSCC cells. 
To the best of our knowledge, it is the first report regard-
ing the effect of ARTA on GJIC in human OSCC.
Recent studies have demonstrated that aberrant GJIC is 
an important step in the carcinogenesis process. Moreo-
ver, GJIC restoration in tumor cells contributes to revers-
ing the transformed phenotype and increases cell growth 
control both in vitro and in vivo. Therefore, prevention of 
GJIC downregulation and restoration of GJIC in tumor 
cells could be a rational chemopreventive approach (22). 
ATRA, trans-resveratrol, growth factors, and green tea 
components have a positive affect on GJIC. These com-
pounds might confer their cancer prevention attributes 
by upregulating Cxs and GJIC (23). Watanabe et al. (24) 
demonstrated that ATRA deregulates GJIC and prevents 
the disruption of GJIC in vitro in renal epithelial cells 
exposed to renal carcinogens. Furthermore, ATRA in-
creases the expression of the Cx43 protein at the plasma 
membrane. These results indicate that one mechanism 
underlying the anti-tumor effect of ATRA in renal epi-
thelial cells is the recovery of GJIC function via the en-
hanced expression and normalized distribution of the 
Cx43 protein. In human hepatoma HepG2 cells, ATRA 
exerts antiproliferative, differentiative, and apoptotic 
effects. Furthermore, ATRA increases the amount and 
phosphorylation of Cxs and enhances GJIC. This sug-
gests that ATRA might be able to reverse cell transfor-
mation in HepG2 cells (6). In this study, we found that 
ATRA could enhance functional gap junctions in OSCC 
cells. Our data is consistent with above reports that show 
ATRA upregulates GJIC in cell systems in vitro. Howev-
er, previous studies have also shown that ATRA impairs 
GJIC in some cell types. ATRA decreases the expression 
of the Cx43 protein and functional gap junctions during 
the neuronal differentiation of p19 embryonic carcinoma 
cells and human pluriopotential teratocarcinoma cells 
(25, 26). George et al. (27) also found that ATRA inhib-
its both cell growth and GJIC at similar doses in human 
cutaneous squamous cell carcinoma SCC-13 cells. How-
ever, to date, the mechanisms responsible for these cell-
type discrepancies are unknown, though they may be 
relative to cell-type–specific transcriptional regulators. 
In addition, specific Cx expression patterns are variable. 
It is possible that a particular Cx may function as a tumor 
modulating protein in one or several specific cell types 
but not in others. More systematic studies are needed to 
explore the precise mechanisms underlying ATRA’s ef-
fects on GJIC in cancer.
According to previous studies and our present findings, 
we propose that ATRA can restore GJIC to some extent. 
However, further studies are required to understand the 
mechanisms by which ATRA alters GJIC in OSCC cells. 
The connexin family comprises the principal mem-
brane components of gap junctions. Connexin proteins 
are expressed in a tissue- and cell-type specific manner. 
In oral mucosal epithelium, although Cx43 and Cx26 
are present (28), other subtypes of Cx have not yet been 
examined. Thus, we used qRT-PCR analysis to evaluate 
the expression of eight Cxs in two OSCC cell lines. Our 
results showed that normal oral epithelial cells had good 
GJIC capability; however, the communication between 
OSCC cells was defective and the levels of the Cx32 and 
Cx43 proteins were decreased. To our knowledge, there 
is little evidence concerning Cx32 expression in oral 
carcinogenesis. In this study, we first demonstrated that 
Cx32 was downregulated in human OSCC cells. Our 
results are consistent with previous reports that indicate 
aberrant gap junction function is correlated with car-
cinogenesis, suggesting that deficiency of GJIC func-
tion may be associated with oral carcinogenesis similar 
to other types of cancers. Next, we measured the ef-
fect of ATRA on the expression of Cx32 and Cx43. In 
our study, qRT-PCR and Western blot analysis demon-
strated that ATRA induced a marked increase in Cx32 
mRNA and protein expression. Fluorescent analysis of 
Cx32 showed that the protein was partially localized to 
the plasma membranes between contacting cells. This 
result suggested that ATRA may also influence Cx32 
relocalization and positioning in the cell membrane of 
OSCC cells. At the current time, there is little evidence 
for an effect of ATRA or other anti-neoplastic agents 
on Cx32 expression in OSCC cells. It has been report-
ed that ATRA enhances Cx32 expression in some cell 
types. For instance, ATRA treatment increases Cx32 
expression and improves the localization of Cx32 to 
Med Oral Patol Oral Cir Bucal. 2013 Jul 1;18 (4):e569-77.                                                                                                                                             ATRA restores GJIC between oral cancer cells
e576
the cell membrane in human hepatocellular carcinoma 
deficient in the expression of Cx32 (6). Other antine-
oplastic agents have also been shown to restore GJIC 
by upregulating Cx32 expression in some cancer cells. 
Fucoxanthin rich in carotenoids inhibits cell prolifera-
tion and enhances GJIC in SK-Hep-1 human hepatoma 
cells, and these effects are associated with upregulation 
of the Cx32 and Cx43 proteins (5). Collectively, these 
results indicate that one possible mechanism for the 
anti-cancer effect of ATRA in OSCC is the recovery of 
GJIC function by enhanced transcriptional expression 
and normalized distribution of the Cx32 protein.
In addition, our studies showed that ATRA treatment in-
duced a significant enhancement in protein and mRNA 
expression of Cx43 in OSCC cells, consistent with pre-
vious reports in some human cancer cells and lens epi-
thelial cells (29) in which the levels of GJIC and Cx43 
expression were increased by ATRA treatment. Indeed, 
several other reports have also demonstrated that Cx43 
can be induced in OSCC cells. Livny et al. found that 
that lycopene, an anticarcinogenic agent, significantly 
upregulated both the transcription and the expression 
of Cx43 and enhanced gap junctional communication 
between oral cancer cells (30). Taken together, these 
results suggested that transcriptional regulation is in-
volved in Cx43 expression in oral cancer cells and that 
ATRA may restore functional GJIC through transcrip-
tional regulation of Cx43 expression in OSCC cells.
Our data showed that ATRA restored GJIC and promot-
ed the mRNA and protein expression of Cx32 and Cx43, 
which is decreased in OSCC cells. These findings indi-
cated that a novel mechanism for the anti-tumor effect 
of ATRA in OSCC cells is restoration of GJIC function 
by enhancing Cx32 and Cx43 expression, although the 
exact mechanisms still require further studies. Restora-
tion of gap junctional communication by ATRA may 
provide new perspectives for ATRA application in hu-
man oral cancer therapy.
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